Literature DB >> 25645114

Treatment of Barrett's esophagus: update on new endoscopic surgical modalities.

I Kristo1, R Asari, E Rieder, V Riegler, S F Schoppmann.   

Abstract

Barrett's esophagus represents a premalignant condition, which is strongly associated with the incidence of esophageal adenocarcinoma. Currently, there are no validated markers to extract exactly that certain patient that will proceed to neoplastic progression. Therefore, therapeutic options have to include a larger population to provide prophylaxis for affected patients. Recently developed endoscopic therapeutic approaches offer treatment options for prevention or even treatment of limited esophageal adenocarcinoma. At present, high eradication rates of intestinal metaplasia as well as dysplasia are observed, whereas low complication rates offer a convenient safety profile. These striking new methods symbolize a changing paradigm in a field, where minimal-invasive tissue ablating methods and tissue preserving techniques have led to modified regimens. This review will focus on current standards and newly emerging methods to treat Barrett's esophagus and its progression to cancer and will highlight their evolution, potential benefits and their limitations.

Entities:  

Mesh:

Year:  2015        PMID: 25645114

Source DB:  PubMed          Journal:  Minerva Chir        ISSN: 0026-4733            Impact factor:   1.000


  3 in total

Review 1.  Does anti-reflux surgery disrupt the pathway of Barrett's esophagus progression to cancer?

Authors:  Sebastian F Schoppmann; Ivan Kristo; Martin Riegler
Journal:  Transl Gastroenterol Hepatol       Date:  2018-12-05

2.  Dietary sugar and Barrett's esophagus.

Authors:  M Riegler; I Kristo; R Asari; E Rieder; S F Schoppmann
Journal:  Eur Surg       Date:  2017-10-24       Impact factor: 0.953

Review 3.  Issues and controversies in esophageal inlet patch.

Authors:  Adriana Ciocalteu; Petrica Popa; Mircea Ionescu; Dan Ionut Gheonea
Journal:  World J Gastroenterol       Date:  2019-08-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.